Known targets — ChEMBL curated mechanism
GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3B
The experimentally established mechanism targets of Memantine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN1 known ✓ | Q05586 | 10/20 | 0.86 |
| ▸ | GRIN2A known ✓ | Q12879 | 10/20 | 0.86 |
| ▸ | GRIN2D known ✓ | O15399 | 9/20 | 0.86 |
| ▸ | GRIN3B known ✓ | O60391 | 9/20 | 0.86 |
| ▸ | GRIN2B known ✓ | Q13224 | 9/20 | 0.86 |
| ▸ | GRIN2C known ✓ | Q14957 | 9/20 | 0.86 |
| ▸ | GRIN3A known ✓ | Q8TCU5 | 9/20 | 0.86 |
| ▸ | LMNA | P02545 | 4/20 | 0.86 |
| ▸ | SLC22A1 | O15245 | 2/20 | 0.86 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.86 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.86 |
| ▸ | ESR1 | P03372 | 1/20 | 0.86 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.86 |
| ▸ | ACHE | P22303 | 1/20 | 0.86 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.86 |
| ▸ | MTOR | P42345 | 1/20 | 0.86 |
| ▸ | HTT | P42858 | 1/20 | 0.86 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.86 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.86 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.86 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Memantine SCHEMBL1374768 | 0.95 | GRIN1 (0.86) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| Memantine SCHEMBL5606188 | 0.93 | GRIN1 (1.00) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| Memantine SCHEMBL2689 | 0.93 | GRIN1 (1.00) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| Memantine SCHEMBL8126868 | 0.93 | GRIN1 (1.00) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| Memantine SCHEMBL13198606 | 0.93 | GRIN1 (1.00) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| Memantine SCHEMBL23327176 | 0.93 | GRIN1 (1.00) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| Memantine SCHEMBL2688 | 0.93 | GRIN1 (1.00) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| Memantine SCHEMBL12959066 | 0.93 | GRIN1 (1.00) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| Memantine SCHEMBL3053 | 0.91 | GRIN1 (1.00) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| Memantine SCHEMBL1659626 | 0.91 | GRIN1 (0.95) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9242009-B2 | Compositions and methods to treat neurodegenerative diseases | THE GENERAL HOSPITAL CORPORATION (US) | 2016-01-26 | — | — | US | disclosed |
| US-20150209438-A1 | COMPOSITIONS AND METHODS TO TREAT NEURODEGENERATIVE DISEASES | THE GENERAL HOSPITAL CORPORATION | 2015-07-30 | — | — | US | disclosed |
| US-8796214-B2 | Neurotrophic peptides | RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC. (US) | 2014-08-05 | — | — | US | disclosed |
| US-8796215-B2 | Neurotrophic peptides | RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC. (US) | 2014-08-05 | — | — | US | disclosed |
| WO-2014015047-A1 | COMPOSITIONS AND METHODS TO TREAT NEURODEGENERATIVE DISEASES | THE GENERAL HOSPITAL CORPORATION (US) | 2014-01-23 | — | — | WO | disclosed |
| US-8592374-B2 | Neurotrophic peptides | RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC. (US) | 2013-11-26 | — | — | US | disclosed |
| US-20130157946-A1 | NEUROTROPHIC PEPTIDES | THE RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC. (US) | 2013-06-20 | — | — | US | disclosed |
| US-20130143809-A1 | NEUROTROPHIC PEPTIDES | THE RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC. (US) | 2013-06-06 | — | — | US | disclosed |
| EP-2588085-A1 | SUSTAINED RELEASE COMPOSITION COMPRISING AN AMINE AS ACTIVE AGENT AND A SALT OF A CYCLIC ORGANIC ACID | Upsher-Smith Laboratories, Inc. (US) | 2013-05-08 | — | — | EP | disclosed |
| EP-2477610-A1 | A SUSTAINED-RELEASE PRODUCT COMPRISING A COMBINATION OF A NON-OPIOID AMINE AND A NON-STEROIDAL ANTI -INFLAMMATORY DRUG | Upsher-Smith Laboratories, Inc. (US) | 2012-07-25 | — | — | EP | disclosed |
| WO-2012003231-A1 | SUSTAINED RELEASE COMPOSITION COMPRISING AN AMINE AS ACTIVE AGENT AND A SALT OF A CYCLIC ORGANIC ACID | UPSHER-SMITH LABORATORIES, INC. (US) | 2012-01-05 | — | — | WO | disclosed |
| US-20110160141-A1 | Neurotrophic Peptides | EVER NEURO PHARMA GMBH (AT) | 2011-06-30 | — | — | US | disclosed |
| WO-2011034554-A1 | A SUSTAINED-RELEASE PRODUCT COMPRISING A COMBINATION OF A NON-OPIOID AMINE AND A NON-STEROIDAL ANTI -INFLAMMATORY DRUG | UPSHER-SMITH LABORATORIES, INC. (US) | 2011-03-24 | — | — | WO | disclosed |
| WO-2003064372-A1 | 2-ADAMANTYLALKYLAMINES AND THEIR USE IN THE TREATMENT OF CONDITIONS GENERALLY ASSOCIATED WITH ABNORMALITIES IN GLUTAMATERGIC TRANSMISSION | VERNALIS RESEARCH LIMITED (GB) | 2003-08-07 | — | — | WO | disclosed |
| EP-1305306-A2 | 2-ADAMANTYLETHYLAMINES AND THEIR USE IN THE TREATMENT OF CONDITIONS GENERALLY ASSOCIATED WITH ABNORMALITIES IN GLUTAMATERGIC TRANSMISSION | VERNALIS RESEARCH LIMITED (GB) | 2003-05-02 | — | — | EP | disclosed |
| WO-2002008219-A2 | 2-ADAMANTYLETHYLAMINES AND THEIR USE IN THE TREATMENT OF CONDITIONS GENERALLY ASSOCIATED WITH ABNORMALITIES IN GLUTAMATERGIC TRANSMISSION | VERNALIS RESEARCH LIMITED (GB) | 2002-01-31 | — | — | WO | disclosed |
| EP-1143964-A1 | 2-ADAMANTANEMETHANAMINE COMPOUNDS FOR TREATING ABNORMALITIES IN GLUTAMATERGIC TRANSMISSION | VERNALIS RESEARCH LIMITED (GB) | 2001-10-17 | — | — | EP | disclosed |
| EP-1051392-A1 | ADAMANTANECARBOXIMIDAMIDE DERIVATIVES AND THEIR USE AS NMDA ANTAGONISTS | VERNALIS RESEARCH LIMITED (GB) | 2000-11-15 | — | — | EP | disclosed |
| WO-2000044371-A1 | 2-ADAMANTANEMETHANAMINE COMPOUNDS FOR TREATING ABNORMALITIES IN GLUTAMATERGIC TRANSMISSION | VERNALIS RESEARCH LIMITED (GB) | 2000-08-03 | — | — | WO | disclosed |
| WO-1999038841-A1 | ADAMANTANECARBOXIMIDAMIDE DERIVATIVES AND THEIR USE AS NMDA ANTAGONISTS | VERNALIS RESEARCH LIMITED (GB) | 1999-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150209438-A1 | COMPOSITIONS AND METHODS TO TREAT NEURODEGENERATIVE DISEASES | PSEN2, SNCA, PSEN1 | GRIN1 431/4885GRIN2A 129/4885GRIN2D 385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.